- Status:
- Red
- Decision Date:
- February 2022
Comments
RED: NICE TA786 - Tucatinib with trastuzumab and capecitabine for treating
HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. (Decision date - May 2022)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
